Global Heart (Apr 2020)

Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry

  • Manlio F. Márquez,
  • Manuel A. Baños-González,
  • Milton E. Guevara-Valdivia,
  • Jorge Vázquez-Acosta,
  • Manuel O. de los Ríos Ibarra,
  • Julio A. Aguilar-Linares,
  • Marcelo Jiménez-Cruz,
  • Norberto Matadamas-Hernández,
  • Rocío Camacho-Casillas,
  • Reynaldo Magaña-Magaña,
  • Ulises Rojel-Martínez,
  • Marco A. Alcocer-Gamba,
  • Susano Lara-Vaca,
  • Humberto Rodríguez-Reyes,
  • Marco A. Islava-Gálvez,
  • Lidia E. Betancourt-Hernández,
  • Nicolás Reyes-Reyes,
  • Miguel E. Beltrán-Gámez,
  • Carlos Cantú-Brito,
  • Alberto Z. Baños-Velasco,
  • Pedro J. del Rivero Morfin,
  • J. Antonio González-Hermosillo

DOI
https://doi.org/10.5334/gh.767
Journal volume & issue
Vol. 15, no. 1

Abstract

Read online

Background: Documenting the patterns of oral anticoagulation therapy (OAT) is essential to prevent thromboembolic complications of nonvalvular atrial fibrillation (NVAF). Objective: To report the patterns of OAT according to age and thromboembolic risk in patients included in CARMEN-AF, a nationwide registry of NVAF in Mexico, an upper middle-income country. Material and methods: There were 1,423 consecutive patients =18 years old and with at least one thromboembolic risk factor enrolled in the CARMEN-AF Registry at their regular clinical visit during a three-year period. They were analyzed according to 1) age, 2) AF type, and 3) CHA2DS2-VASc score. Results: Overall, 16.4% of patients did not receive antithrombotic treatment, 19.4% received antiplatelet drugs (APD), 29.2% vitamin K antagonists (VKA), and 34.6% direct oral anticoagulants (DOAC). With increasing age, the proportion of subjects treated with VKA decreased significantly from 36.2% in subjects 2DS2-VASc =2) compared with the moderate risk group (41% in CHA2DS2-VASc = 1). Conclusions: VKA use for NVAF in Mexico decreased in relation to increasing age. The proportion of DOAC therapy was the same in all age groups. Nevertheless, elderly patients with high thromboembolic risk received a suboptimal thromboprophylaxis. These data could help to improve gaps in the implementation of global guidelines. Clinical trial registration: http://www.clinicaltrials.gov. Unique identifier: NCT02334852. Highlights: CARMEN-AF is a nationwide multi-centric registry seeking to bridge the data gap on anticoagulation therapy for NVAF in Mexico. Elderly patients are more prone to receive suboptimal OAT for NVAF. DOAC were less frequently used in high thromboembolic risk patients (CHA2DS2-VASc =2).

Keywords